The estimated Net Worth of Scott William Drake is at least $1.59 Millón dollars as of 18 July 2023. Mr Drake owns over 2,408,747 units of ViewRay stock worth over $39,790 and over the last 11 years he sold VRAY stock worth over $144,525. In addition, he makes $1,406,115 as Pres y CEO & Director at ViewRay.
Mr has made over 11 trades of the ViewRay stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 2,408,747 units of VRAY stock worth $144,525 on 18 July 2023.
The largest trade he's ever made was selling 2,408,747 units of ViewRay stock on 18 July 2023 worth over $144,525. On average, Mr trades about 59,075 units every 38 days since 2013. As of 18 July 2023 he still owns at least 1,591,615 units of ViewRay stock.
You can see the complete history of Mr Drake stock trades at the bottom of the page.
Scott William Drake is the Pres, CEO & Director at ViewRay.
As the Pres y CEO & Director of ViewRay, the total compensation of Mr Drake at ViewRay is $1,406,115. There are no executives at ViewRay getting paid more.
Mr Drake is 53, he's been the Pres y CEO & Director of ViewRay since . There are 1 older and 3 younger executives at ViewRay. The oldest executive at ViewRay Inc. is Robert Michael Fuchs, 54, who is the Chief HR Officer.
Scott's mailing address filed with the SEC is C/O VIEWRAY, INC., 1099 18TH STREET, SUITE 3000, DENVER, CO, 80202.
Over the last 9 years, insiders at ViewRay have traded over $157,178,869 worth of ViewRay stock and bought 23,644,461 units worth $89,494,703 . The most active insiders traders include David P Bonita, International Ltd Fosun y Influence Ltd Strong. On average, ViewRay executives and independent directors trade stock every 35 days with the average trade being worth of $20,317. The most recent stock trade was executed by B Kristine Johnson on 21 July 2023, trading 30,702 units of VRAY stock currently worth $1,535.
mri-guided adaptive radiotherapy viewray®, inc. (nasdaq:vray), designs, manufactures, and markets the mridian® radiation therapy system to address the key limitations of existing external-beam radiation therapy technologies. mridian employs mri-based technology to provide real-time imaging that clearly defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. mridian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription as needed. viewray believes this combination of enhanced visualization, on-line adapting and accurate dose recording will significantly improve the safety and efficacy of radiation therapy, leading to better outcomes for patients. at viewray, our vision is clear. we’re dedicated to giving doctors new and better ways to treat cancer with radiation therapy. we’re an entrepreneurial company with big ambitions, unlimited potential and a passion for improving
ViewRay executives and other stock owners filed with the SEC include: